secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2026-05-14T12:50:28+00:00
Accession:  0001104659-26-060747
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026
----------------------------------------------------------------

- Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.
- Cash $13.2M provides runway into Q4 2026; closed $12.5M of a $26.9M financing in Jan 2026.
- Halneuron Phase 2b in CINP: 164 enrolled, top-line results expected fall 2026.
- SP16 IND approved; Phase 1b in CIPPN funded by NCI, enrollment starts mid-2026.
- Announced global partnership for legacy antiviral assets with potential value up to $100M to Dogwood and shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/0001104659-26-060747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/dwtx-20260514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-060747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer